



August 12, 2007

Allen F. Gant
CEO and Chairman
BioMarck Pharmaceuticals
2619 St. Mary's Street
Raleigh, NC 27609

Dear Mr. Gant,

It is my pleasure to write this letter commenting on the exciting research conducted by Dr. Kenneth Adler from the North Carolina State University and BioMarck Corporation.

It is well known that Chronic Obstructive Pulmonary Disease (COPD) is a devastating illness and the 4th leading cause of death in the US. It is projected to become the 3rd leading cause in 5 years which points out the need to develop novel and more effective therapies for this debilitating disease. As a physician/scientist investigating lung diseases, I am well aware of the innovative and important research conducted by Dr. Adler and his colleagues and can confidently state that Dr. Adler is an outstanding investigator who is greatly contributing to our understanding of COPD. He is a thought leader with an impeccable scientific reputation in the field of lung biology-translational research.

The novel findings of his laboratory showing that inhibition of the MARCKS-related peptide prevented mucus secretion and improved lung function in animal models of mucus hypersecretion was published in Nature Medicine, the most prestigious scientific publication in this area of research. Dr. Adler's discovery has significant clinical implications and the potential of this finding is very important, since there is not much in the armamentarium of a clinician to treat COPD patients to control mucus secretion which is a major contributor to the morbidity of these patients. As such, I am pleased to learn that the research group led by Dr. Adler is focusing on this novel COPD therapeutic strategy which has the potential to improve morbidity and mortality of this patient population.

Sincerely,

A handwritten signature in black ink, appearing to read "J. Sznajder".

Jacob I. Sznajder, MD